https://orcid.org/0000-0001-8318-2783
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Tetsuro Ikegami. (2019) Candidate vaccines for human Rift Valley fever. Expert Opinion on Biological Therapy 19:12, pages 1333-1342.
Read now
Read now
Articles from other publishers (32)
Cigdem Alkan, Eduardo Jurado-Cobena & Tetsuro Ikegami. (2023) Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates. npj Vaccines 8:1.
Crossref
Crossref
Selvaraj Pavulraj, Rhett W. Stout, Elise D. Barras, Daniel B. Paulsen & Shafiqul I. Chowdhury. (2023) A Novel Quadruple Gene-Deleted BoHV-1-Vectored RVFV Subunit Vaccine Induces Humoral and Cell-Mediated Immune Response against Rift Valley Fever in Calves. Viruses 15:11, pages 2183.
Crossref
Crossref
Matome Selina Matsiela, Leeann Naicker, Thandeka Khoza & Nobalanda Mokoena. (2023) Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep. Virology Journal 20:1.
Crossref
Crossref
Niranjana Nair, Albert D. M. E. Osterhaus, Guus F. Rimmelzwaan & Chittappen Kandiyil Prajeeth. (2023) Rift Valley Fever Virus—Infection, Pathogenesis and Host Immune Responses. Pathogens 12:9, pages 1174.
Crossref
Crossref
Alexander Bowmer, Joseph Ssembatya, Mark Okot, Richard Bagyenyi, Stephen Venny Rubanga & Gladys Kalema-Zikusoka. (2023) Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II/III clinical trials in Uganda. One Health 16, pages 100470.
Crossref
Crossref
Mathilde Laureti, Rui-Xue Lee, Amelia Bennett, Lucas Aladar Wilson, Victoria Elena Sy, Alain Kohl & Isabelle Dietrich. (2023) Rift Valley Fever Virus Primes Immune Responses in Aedes aegypti Cells. Pathogens 12:4, pages 563.
Crossref
Crossref
Paul J. Wichgers Schreur, Brian H. Bird, Tetsuro Ikegami, Erick Bermúdez-Méndez & Jeroen Kortekaas. (2023) Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use. Vaccines 11:3, pages 707.
Crossref
Crossref
Victoria B. AyersYan-Jang S. HuangJames I. DunlopAlain KohlBenjamin Brennan, Stephen HiggsDana L. Vanlandingham. (2023) Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome. Viral Immunology 36:1, pages 33-40.
Crossref
Crossref
Jiajing Wu, Weijin Huang & Youchun Wang. 2023. Pseudotyped Viruses. Pseudotyped Viruses
253
264
.
Douglas M. WattsJonna L.B. WestoverPedro M. PalermoKevin W. BaileyJohn C. MorrillGeorge E. BettingerThomas P. MonathDarci R. SmithClarence J. PetersPhillip R. Pittman, Jeanette OrbegozoBrian B. Gowen. (2022) Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. The American Journal of Tropical Medicine and Hygiene 107:5, pages 1091-1098.
Crossref
Crossref
J.C. Morrill, C.J. Peters, G.E. Bettinger, P.M. Palermo, D.R. Smith & D.M. Watts. (2022) Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice. Vaccine 40:50, pages 7255-7261.
Crossref
Crossref
Q. Mehmood, M. Irfan, I. Olushola Ogunkola, F. Jaguga & I. Ullah. (2021) Rift valley fever and COVID-19 outbreak in Kenya: A double whammy. Ethics, Medicine and Public Health 19, pages 100685.
Crossref
Crossref
Tetsuro Ikegami. (2021) Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics System for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells. Journal of Virology 95:7.
Crossref
Crossref
Belén Borrego & Alejandro Brun. (2021) A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers. Frontiers in Microbiology 11.
Crossref
Crossref
Corey R. Nelson, Tyler Mrozowich, Sean M. Park, Simmone D’souza, Amy Henrickson, Justin R. J. Vigar, Hans-Joachim Wieden, Raymond J. Owens, Borries Demeler & Trushar R. Patel. (2020) Human DDX17 Unwinds Rift Valley Fever Virus Non-Coding RNAs. International Journal of Molecular Sciences 22:1, pages 54.
Crossref
Crossref
Breanna Tercero & Shinji Makino. (2020) Reverse genetics approaches for the development of bunyavirus vaccines. Current Opinion in Virology 44, pages 16-25.
Crossref
Crossref
Vincent Mastrodomenico, Jeremy J. Esin, Shefah Qazi, Maxim A. Khomutov, Alexander V. Ivanov, Suchetana Mukhopadhyay & Bryan C. Mounce. (2020) Virion-Associated Polyamines Transmit with Bunyaviruses to Maintain Infectivity and Promote Entry. ACS Infectious Diseases 6:9, pages 2490-2501.
Crossref
Crossref
Elysse N. Grossi-Soyster & A. Desiree LaBeaud. (2020) Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks. Tropical Medicine and Infectious Disease 5:2, pages 89.
Crossref
Crossref
Andrea Louise Kroeker, Shawn Babiuk, Bradley S. Pickering, Juergen A. Richt & William C. Wilson. (2020) Livestock Challenge Models of Rift Valley Fever for Agricultural Vaccine Testing. Frontiers in Veterinary Science 7.
Crossref
Crossref
Zachary J. Sandler, Mason R. Firpo, Oreoluwa S. Omoba, Michelle N. Vu, Vineet D. Menachery & Bryan C. Mounce. (2020) Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Oxana Selina, Ilnaz Imatdinov, Vera Balysheva, Roman Akasov, Alexander Kryukov, Vladimir Balyshev & Elena Markvicheva. (2020) Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice. Biotechnology Letters 42:4, pages 529-536.
Crossref
Crossref
Søren Saxmose Nielsen, Julio Alvarez, Dominique Joseph Bicout, Paolo Calistri, Klaus Depner, Julian Ashley Drewe, Bruno Garin‐Bastuji, José Luis Gonzales Rojas, Christian Gortázar Schmidt, Virginie Michel, Miguel Ángel Miranda Chueca, Helen Clare Roberts, Liisa Helena Sihvonen, Karl Stahl, Antonio Velarde Calvo, Arvo Viltrop, Christoph Winckler, Bernard Bett, Catherine Cetre‐Sossah, Veronique Chevalier, Clazien Devos, Simon Gubbins, Federica Monaco, Antoniou Sotiria‐Eleni, Alessandro Broglia, José Cortiñas Abrahantes, Sofie Dhollander, Yves Van Der Stede & Gabriele Zancanaro. (2020) Rift Valley Fever – epidemiological update and risk of introduction into Europe. EFSA Journal 18:3.
Crossref
Crossref
Edna Mutua, Nicoline de Haan, Dan Tumusiime, Christine Jost & Bernard Bett. (2019) A Qualitative Study on Gendered Barriers to Livestock Vaccine Uptake in Kenya and Uganda and Their Implications on Rift Valley Fever Control. Vaccines 7:3, pages 86.
Crossref
Crossref
Daniel Wright, Jeroen Kortekaas, Thomas A. Bowden & George M. Warimwe. (2019) Rift Valley fever: biology and epidemiology. Journal of General Virology 100:8, pages 1187-1199.
Crossref
Crossref
Z. Boumart, S. Daouam, Z. Bamouh, M. Jazouli, K.O Tadlaoui, B. Dungu, G. Bettinger, D.M. Watts & M. Elharrak. (2019) Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves. Vaccine 37:12, pages 1642-1650.
Crossref
Crossref
Mohamed A. Hussein, Haytham A. Ali, Bahgat A. Abd El-Rhman, Timour N. Morcoss, Ahmed Elsadek Fakhr, Ayman Abdel Aziz Swelum, Abdullah Alowaimer, Hammed A. Tukur & Islam M. Saadeldin. (2019) Efficacy of Montanide (IMS 3015) as an adjuvant for an inactivated Rift Valley fever (RVF) vaccine in sheep. Acta Tropica 190, pages 193-203.
Crossref
Crossref
Kaori Terasaki, Terry L. Juelich, Jennifer K. Smith, Birte Kalveram, David D. Perez, Alexander N. Freiberg & Shinji Makino. (2018) A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice. Scientific Reports 8:1.
Crossref
Crossref
Baptiste Dungu, Baratang A Lubisi & Tetsuro Ikegami. (2018) Rift Valley fever vaccines: current and future needs. Current Opinion in Virology 29, pages 8-15.
Crossref
Crossref
Tetsuro Ikegami, Aaron Balogh, Shoko Nishiyama, Nandadeva Lokugamage, Tais B. Saito, John C. Morrill, Vinay Shivanna, Sabarish V. Indran, Lihong Zhang, Jennifer K. Smith, David Perez, Terry L. Juelich, Igor Morozov, William C. Wilson, Alexander N. Freiberg & Juergen A. Richt. (2017) Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLOS ONE 12:12, pages e0189250.
Crossref
Crossref
Hoai J. Ly, Shoko Nishiyama, Nandadeva Lokugamage, Jennifer K. Smith, Lihong Zhang, David Perez, Terry L. Juelich, Alexander N. Freiberg & Tetsuro Ikegami. (2017) Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain. Vaccine 35:48, pages 6634-6642.
Crossref
Crossref
Utpal Kumar Adhikari & M. Mizanur Rahman. (2017) Overlapping CD8 + and CD4 + T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach. Infection, Genetics and Evolution 56, pages 75-91.
Crossref
Crossref
Colm Atkins & Alexander N Freiberg. (2017) Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. Future Virology 12:11, pages 651-665.
Crossref
Crossref